3,293 results on '"Lammert, Frank"'
Search Results
2. Screening for liver fibrosis: lessons from colorectal and lung cancer screening
3. Use of complementary and alternative medicine in patients with chronic liver diseases in Germany- a multicentric observational study
4. Skin advanced glycation end-products as indicators of the metabolic profile in diabetes mellitus: correlations with glycemic control, liver phenotypes and metabolic biomarkers
5. Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis
6. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
7. Intra-pituitary follicle-stimulating hormone signaling regulates hepatic lipid metabolism in mice
8. Alpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ)
9. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy‐proven non‐alcoholic fatty liver disease
10. Pathophysiologie: Genetik
11. Presence of NOD2 mutations is not associated with hepatic or systemic hemodynamic abnormalities of cirrhosis
12. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
13. A mixed-methods study to define Textbook Outcome for the treatment of patients with uncomplicated symptomatic gallstone disease with hospital variation analyses in Dutch trial data
14. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B
15. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
16. TOP-241-YI Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5, 517 participants
17. SAT-087-YI The presence of NOD2 risk variants is associated to a higher incidence of first decompensation in patients with cirrhosis and varices
18. The ABCG8 polymorphism increases the risk of gallbladder cancer in the general population and gallstones in obese patients from Poland
19. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
20. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project
21. TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study
22. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL
23. Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial
24. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
25. Impact of Endocrine Disorders on the Liver
26. S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV).
27. 4 Effekte des Alterns auf den Gastrointestinaltrakt
28. Retrospective study of the incidence, risk factors, treatment outcomes of bacterial infections at uncommon sites in cirrhotic patients
29. Letter to the Editor: NAFLD vs. MASLD—There ain’t no such thing as a free lunch
30. Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis
31. Leber und Schwangerschaft
32. Visualising and quantifying intestinal permeability -where do we stand
33. Volume–Function Analysis (LiMAx Test) in Patients with HCC and Cirrhosis Undergoing TACE—A Feasibility Study
34. Schwangerschaftscholestase: In Zusammenarbeit mit der AG Geburtshilfe und Pränatalmedizin in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – Sektion Maternale Erkrankungen
35. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care
36. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
37. Hepatic consequences of COVID-19 infection. Lapping or biting?
38. Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study
39. Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele
40. Corrigendum to ‘A mixed-methods study to define Textbook Outcome for the treatment of patients with uncomplicated symptomatic gallstone disease with hospital variation analyses in Dutch trial data’ [Volume 25, Issue 9, September 2023, Pages 1000–1010]
41. Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study
42. Childhood obesity, cardiovascular and liver health: a growing epidemic with age
43. MicroRNA-496 and Mechanistic Target of Rapamycin Expression are Associated with Type 2 Diabetes Mellitus and Obesity in Elderly People
44. MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis
45. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group
46. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia
47. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
48. Autoren
49. Maternale Erkrankungen in der Schwangerschaft
50. Genetics of Polygenic Metabolic Liver Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.